Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 28.7% in March

Evogene Ltd. (NASDAQ:EVGN) was the target of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 242,174 shares, a growth of 28.7% from the February 26th total of 188,218 shares. Based on an average daily trading volume, of 188,709 shares, the short-interest ratio is presently 1.3 days. Approximately 4.9% of the company’s stock are short sold.

Evogene Stock Performance

Evogene stock opened at $0.82 on Monday. Evogene has a fifty-two week low of $0.73 and a fifty-two week high of $2.42. The stock’s 50 day simple moving average is $0.92 and its two-hundred day simple moving average is $1.08. The stock has a market cap of $4.40 million, a price-to-earnings ratio of -0.70 and a beta of 1.36.

Evogene (NASDAQ:EVGN) last announced its earnings results on Saturday, February 14th. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million during the quarter. Evogene had a negative return on equity of 121.44% and a negative net margin of 214.57%.

Hedge Funds Weigh In On Evogene

A number of institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC lifted its position in Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the period. Jane Street Group LLC grew its position in shares of Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Evogene in the 4th quarter worth about $25,000. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.